Feature | March 24, 2011| Keith G. Boman, M.D., FACC

Sudden Cardiac Arrest in Patient With Moderate LV Dysfunction and Positive MTWA Test

Figure 1: Positive MTWA test result

Figure 2: Patients ICD electrocardiogram

During a sudden cardiac arrest (SCA), heart function ceases – abruptly and without warning – most often due to the onset of a ventricular tachyarrhythmia [1]. Because out-of-hospital survival is less than 8 percent, prediction and prevention are critically important [2]. Microvolt T-wave alternans (MTWA), a subtle alternating pattern in T-wave morphology on the surface electrocardiogram is a marker of arrhythmic vulnerability and SCA risk [3, 4], demonstrating prognostic value in various patient populations including those with ischemic and non-ischemic cardiomyopathy [5-7]. We report a case of a patient who experienced SCA one year after a positive MTWA test.

Case History
An asymptomatic 64-year-old male had a history of coronary artery disease and coronary bypass surgery in 1992. A computed tomography (CT) angiogram performed in September 2006 revealed subtotal occlusion of the right coronary artery; however, angioplasty could not be completed due to anatomical complexity. An echocardiogram showed a left ventricular ejection fraction (LVEF) of 45-50 percent and significant left ventricular hypertrophy secondary to moderate aortic stenosis. Given his clinical profile, an MTWA test was ordered to further clarify his risk of ventricular arrhythmias and SCA.

MTWA Study and Follow-up
In October 2009, MTWA testing was performed with treadmill exercise using the Analytic Spectral Method to measure alternans (HearTwave II, Cambridge Heart, Tewksbury, Mass.). At the time of the test, the patient was in normal sinus rhythm with intermittent ventricular ectopy. The MTWA result was positive with sustained alternans present in several leads with an onset heart rate of 106 bpm (Fig. 1). The positive MTWA study along with the patient’s other risk factors prompted an evaluation by an electrophysiologist.

An electrophysiology study (EPS) was performed resulting in inducible ventricular tachycardia with two extrastimuli, and a dual-chamber implantable cardioverter defibrillator (ICD) (Secura DR, Medtronic, Minneapolis, Minn.) was implanted in November 2009. One year later while resting at home, the patient reported feeling a “flutter” in his heart followed by a shock from the device. Review of the ICD electrogram (Fig. 2) confirmed that the patient experienced an episode of ventricular fibrillation which was successfully terminated by a 23.7 J defibrillation shock on Dec. 2, 2010.

Discussion
Reduced left ventricular ejection fraction is an established risk factor for cardiac arrest and is currently the primary determinant of ICD eligibility; however, EF lacks sensitivity [8] due to the fact that the majority of SCA deaths occur in patients with an EF more than 30-35 percent [9, 10]. This patient did not have significant LV dysfunction, but had several other clinical factors associated with increased risk of SCA including ischemic cardiomyopathy [11], left ventricular hypertrophy [12] and aortic stenosis [13].

MTWA has been cited as a useful adjunct tool in such patients with moderate to preserved LVEF for whom SCA is a “real but difficult-to-ascertain risk” [14]. MTWA can help guide SCA risk management strategies which may include treatment of underlying ischemia, medical optimization, tighter glucose control, lifestyle changes – or, when appropriate, EPS referral and possible EPS or ICD implantation.

“Per current primary prevention guidelines, this patient would not have received life-saving ICD therapy if he had not undergone an MTWA study,” noted Keith Boman, M.D., the patient’s cardiologist. “MTWA is a tool to help clarify the overall arrhythmic risk, particularly for patients who have known risk factors but who fall into this ‘gray area’ in terms of ICD eligibility.”

References
1. Bayes de Luna A, Coumel P, and Leclercq JF. "Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases." Am Heart J, 1989; 117(1): 151-9.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. "Heart disease and stroke statistics--2010 update: a report from the American Heart Association." Circulation; 121(7): e46-e215.
3. Pastore JM, Girouard SD, Laurita KR, Akar FG, and Rosenbaum DS. "Mechanism linking T-wave alternans to the genesis of cardiac fibrillation." Circulation, 1999; 99(10): 1385-94.
4. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, and Cohen RJ. "Electrical Alternans and Vulnerability to Ventricular Arrhythmias." N Engl J Med, 1994; 330(4): 235-241.
5. Chow T, Kereiakes DJ, Bartone C, et al. "Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy." J Am Coll Cardiol, 2006; 47(9): 1820-7.
6. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al. Prognostic Value of T-Wave Alternans in Patients With Heart Failure Due to Nonischemic Cardiomyopathy: Results of the ALPHA Study. J Am Coll Cardiol 2007; 50(19): 1896-1904.
7. Bloomfield DM, Bigger JT, Steinman RC, et al. "Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction." J Am Coll Cardiol, 2006; 47(2): 456-63.
8. Buxton AE, Lee KL, Hafley GE, et al. "Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study." J Am Coll Cardiol, 2007; 50(12): 1150-7.
9. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. "Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival." J Am Coll Cardiol, 1997; 30(6): 1500-5.
10. Stecker EC, Vickers C, Waltz J, et al. "Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study." J Am Coll Cardiol, 2006; 47(6): 1161-6.
11. Huikuri HV, Castellanos A, and Myerburg RJ. "Sudden death due to cardiac arrhythmias." N Engl J Med, 2001; 345(20): 1473-82.
12. Haider AW, Larson MG, Benjamin EJ, and Levy D. "Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death." J Am Coll Cardiol, 1998; 32(5): 1454-9.
13. Kulbertus HE. "Ventricular arrhythmias, syncope and sudden death in aortic stenosis." European Heart Journal 1988; 9(suppl E): 51-52.
14. Mirro MJ. "Strategies for reducing sudden cardiac death: Application of microvolt T-wave alternans testing in clinical practice." Heart Rhythm, 2009; 6(3): S45-S48.

This case study was supplied by Cambridge Heart

For more information: www.cambridgeheart.com

Related Content

EpiAccess System, EpiEP, Mount Sinai New York, epicardial access
News | Ablation Systems| August 22, 2016
August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new appro
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
News | EP Lab| August 12, 2016
August 12, 2016 — Electrophysiology ablation navigation system company Stereotaxis Inc.
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders| August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in th
pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 26, 2016 | Heidi Olson, Pharm.D
With the recent introduction of several novel oral...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init